Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation, commonly known as AGTC, was a United States biotechnology company founded in 1999 and headquartered in Alachua, Florida. Its work centered on genetic medicines for ophthalmic diseases, particularly inherited retinal disorders for which conventional small-molecule or protein therapies offered limited options. The company used viral gene-delivery approaches, including adeno-associated virus-based technology, to investigate whether functional genetic material could be delivered to retinal cells and potentially address the molecular causes of disease. AGTC operated primarily as a development-stage biotechnology business rather than as a commercial pharmaceutical company. Its publicly described pipeline covered candidate therapies for achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and age-related macular degeneration. By 2016, the company reported six products at different stages of development, but none had received regulatory approval. This meant that AGTC’s identity and valuation were tied mainly to its delivery platform, clinical data, intellectual property, and partnerships rather than to recurring sales from marketed medicines. The company’s ophthalmology focus was supported by clinical and translational work in rare retinal diseases. In 2017, AGTC entered a strategic research and development collaboration with Bionic Sight, a company working in optogenetics and retinal coding. The collaboration was intended to combine AGTC’s gene-therapy and ophthalmology capabilities with Bionic Sight’s work on optogenetic treatment approaches. AGTC also described itself as a patient partner in the blinding-eye-disease and rare-disease communities, with links to organizations such as the Foundation Fighting Blindness and Global Genes. AGTC continued to report clinical progress in the late 2010s and early 2020s. In January 2020, it announced positive results from a Phase 1/2 study of an investigational gene therapy for retinitis pigmentosa. It subsequently reported interim six-month data from dose-escalation cohorts in Phase 1/2 programs for achromatopsia associated with mutations in the CNGB3 and CNGA3 genes. These announcements represented clinical-development updates, not evidence of an approved or commercially available treatment. In June 2019, AGTC announced that Theresa G. H. Heah, M.D., M.B.A., a clinical and medical affairs executive, would join the company as chief medical officer. The appointment reflected the company’s emphasis on advancing ophthalmic gene-therapy programs through clinical development. AGTC remained a publicly traded company and was included in the NASDAQ Biotechnology Index during its independent corporate period. AGTC was acquired by Syncona Limited on December 1, 2022. Following that transaction, AGTC ceased to operate as an independent publicly traded company and its former public-company identity and ticker no longer represented a standalone listed issuer. The available reference material does not establish the subsequent commercial status of each AGTC program or whether the AGTC brand continued as a separate operating brand within Syncona’s portfolio.

Applied Genetic Technologies Corporation was established in 1999 as a biotechnology company focused on genetic medicines. Its headquarters were in Alachua, Florida, and its public-company activities were associated with the biotechnology sector and the NASDAQ Biotechnology Index. AGTC’s corporate strategy was built around the development of gene therapies for ophthalmic disease, especially inherited retinal disorders in which a defined genetic defect could provide a target for replacement or augmentation therapy. The company’s technology work included adeno-associated virus-based gene delivery. Rather than selling a finished medicine, AGTC used this platform to create investigational therapies intended to transport functional genetic material to relevant retinal cells. Its development portfolio included programs directed at achromatopsia, X-linked retinoschisis, X-linked retinitis pigmentosa, and age-related macular degeneration. By 2016, six products were described as being in different stages of development, while none had yet received regulatory approval. AGTC therefore remained dependent on research progress, clinical outcomes, regulatory execution, and business relationships rather than established product revenue. A significant partnership milestone came in January 2017, when AGTC entered a strategic research and development collaboration with Bionic Sight. The collaboration addressed optogenetics and retinal coding, an emerging area that seeks to use light-sensitive biological mechanisms and neural coding concepts in the treatment of vision loss. The relationship broadened the scientific scope of AGTC’s ophthalmology activities while retaining a connection to its gene-therapy expertise. AGTC also developed a role in the rare-disease and blinding-eye-disease communities. The company identified itself as a patient partner and was associated with organizations including the Foundation Fighting Blindness and Global Genes. These relationships reflected the importance of patient identification, natural-history knowledge, genetic diagnosis, and trial recruitment in rare ophthalmic conditions. The company expanded its clinical leadership in June 2019 by announcing Theresa G. H. Heah, M.D., M.B.A., as chief medical officer. Her appointment came as AGTC continued to advance clinical programs and reflected the need for specialized medical, regulatory, and trial-development expertise. In January 2020, AGTC announced positive results from a Phase 1/2 trial of an investigational therapy for retinitis pigmentosa. It later reported interim six-month results from dose-escalation cohorts in Phase 1/2 achromatopsia programs involving CNGB3 and CNGA3 mutations. These reports marked clinical-development milestones but did not constitute regulatory approvals or commercial launches. AGTC was ultimately acquired by Syncona Limited on December 1, 2022. The transaction ended the company’s period as an independent public corporation and means that AGTC should be treated as a defunct standalone listed company in an encyclopedia of corporate brands. The supplied reference material does not provide a complete account of the transaction terms, the post-acquisition treatment of individual programs, or the continuing use of the AGTC name. Those details are therefore left unspecified.

1. 2022Acquired by Syncona

   Syncona completed its acquisition of AGTC on December 1, ending AGTC’s independent public-company status.

   Source
2. 2020Retinitis pigmentosa Phase 1/2 data reported

   The company announced positive results from a Phase 1/2 trial of an investigational gene therapy for retinitis pigmentosa.

   Source
3. 2019New chief medical officer appointed

   AGTC announced that Theresa G. H. Heah would join as chief medical officer.

   Source
4. 2017Bionic Sight collaboration

   AGTC entered a strategic research and development collaboration with Bionic Sight covering optogenetics and retinal coding.

   Source
5. 2016Six development programs reported

   AGTC was described as having six products in various development stages, with none approved at that time.

   Source
6. 1999Company founded

   Applied Genetic Technologies Corporation was founded as a biotechnology company focused on genetic medicines.

   Source

A development-stage gene-therapy company focused on inherited retinal and other ophthalmic diseases, using viral gene-delivery technologies and clinical partnerships to pursue treatments for rare and blinding conditions.

• Achromatopsia gene-therapy programsgene therapy

  AGTC developed investigational programs for achromatopsia, an inherited retinal disorder involving impaired cone-cell function. Its clinical work included programs associated with CNGB3 and CNGA3 mutations, with interim six-month data reported from dose-escalation cohorts. These were clinical-stage candidates and not approved commercial products.

• Retinitis pigmentosa gene-therapy programsgene therapy

  AGTC investigated gene-therapy approaches for retinitis pigmentosa, including X-linked retinitis pigmentosa. In January 2020, the company reported positive results from a Phase 1/2 study of an investigational therapy. The program remained an investigational clinical asset rather than an approved treatment in the supplied sources.

• X-linked retinoschisis programgene therapy

  X-linked retinoschisis was among the inherited ophthalmic diseases targeted by AGTC’s technology and product-development strategy. The program was intended to explore gene delivery for a rare retinal condition, but the supplied material does not provide a confirmed product name, launch date, approval, or final development outcome.

• AAV gene-delivery platformbiotechnology platform

  AGTC’s platform included adeno-associated virus-based gene delivery for transporting therapeutic genetic material to target tissues. The approach supported programs in inherited retinal disease and other ophthalmic conditions. It was a research and development technology, not a separately marketed consumer product.

• 2022Acquisition by SynconaM&A

  AGTC remained a development-stage public biotechnology company with investigational ophthalmic gene-therapy assets.

  What changed. Syncona acquired Applied Genetic Technologies Corporation, with the transaction completed on December 1, 2022.

  Aftermath. AGTC ceased to exist as an independent publicly traded company. The supplied material does not specify the subsequent status of each program or the financial terms of the acquisition.

  Source
• 2017Expand ophthalmic gene-therapy research through Bionic Sight collaborationStrategy

  AGTC sought to broaden its ophthalmology research beyond conventional gene-replacement programs by engaging with optogenetics and retinal coding.

  What changed. The company entered a strategic research and development collaboration with Bionic Sight to pursue an optogenetic therapy combining Bionic Sight’s scientific work with AGTC’s gene-therapy and ophthalmology capabilities.

  Aftermath. The collaboration was reported as part of AGTC’s research strategy; the supplied material does not establish a subsequent approved product or commercial launch from it.

  Source

• 2022Syncona acquires Applied Genetic Technologies Corporation

  Syncona completed the acquisition of AGTC on December 1, 2022, ending AGTC’s existence as an independent publicly traded company.

  M&A
  Source
• 2020AGTC reports positive Phase 1/2 retinitis pigmentosa results

  The company reported positive results from a Phase 1/2 clinical trial evaluating an investigational gene therapy for retinitis pigmentosa.

  Other
  Source
• 2020AGTC reports interim achromatopsia clinical data

  AGTC released interim six-month data from dose-escalation cohorts in Phase 1/2 programs for achromatopsia associated with CNGB3 and CNGA3 mutations.

  Other
  Source
• 2019AGTC appoints Theresa G. H. Heah as chief medical officer

  AGTC announced the appointment of Theresa G. H. Heah, a clinical and medical affairs executive, to lead the company’s medical and clinical-development activities.

  Leadership change
  Source
• 2017AGTC and Bionic Sight establish an optogenetics research collaboration

  The companies entered a strategic research and development collaboration intended to combine AGTC’s ophthalmic gene-therapy capabilities with Bionic Sight’s work in optogenetics and retinal coding.

  Other
  Source

1. Applied Genetic Technologies Corporation
2. Applied Genetic Technologies Corporation official website